AbbVie Stock: Shares Fall by 2.79% at Close

Continued Downward Trend on Monday

Monday's session on November 3 extended the unfavorable trend marked by the announcement of quarterly results. Trading volume stood at 8.87 million shares, representing 0.5% of the market capitalization. This high level of trading indicates some portfolio repositioning activity following the data revealed last Friday. On an annual basis, AbbVie has recorded a growth of 5.73%, a performance that demonstrates some resilience despite the turbulence observed over the week. In comparison, the S&P 500 has advanced 18.33% over the past twelve months, clearly highlighting the growing gap between pharmaceutical stocks and the broader gains of the American market, largely driven by the technology sector. This divergence reflects the specific challenges faced by the pharmaceutical sector, including patent expirations and the emergence of generics and biosimilars. The stock has been performing well below market averages for several months, a period during which AbbVie has had to accelerate the reshaping of its product portfolio to offset revenue declines due to the loss of exclusivity of its flagship treatments. The cumulative decline of 7.05% over the week reveals the magnitude of the ongoing correction. While the pharmaceutical sector generally displays stable valuations due to their predictable cash flows, portfolio change cycles can generate more pronounced volatilities. AbbVie is an example this week, with the S&P 500 making modest gains on Monday while the stock declines.

Weekly Decline Directly Attributable to Quarterly Results

The bearish week is directly attributable to the quarterly results unveiled on October 31. AbbVie reported a net profit of $186 million for the third quarter of 2025, a dramatic drop compared to the $1.56 billion achieved a year earlier. This decline is particularly due to the unfavorable impacts related to research and development expenses, which weighed at $1.50 per share on the quarterly results. However, the adjusted results paint a different picture. The group recorded an adjusted earnings per share of $1.86, clearly surpassing the analysts' estimates set at $1.77. The quarterly revenue of $15.78 billion also exceeded the consensus expectations of $15.59 billion. In light of this performance exceeding expectations, AbbVie has decided to raise its 2025 annual profit forecast, setting it at $10.61 to $10.65 per share, compared to an initial range of $10.38 to $10.58. This upward revision acknowledges the strength of the group's new immunological treatments. Sales of Skyrizi reached $4.71 billion, exceeding the expected $4.44 billion, while Rinvoq generated $2.18 billion, also surpassing the forecasts of $2.12 billion. These two drugs are now the growth drivers for the group. Meanwhile, the inevitable decline of Humira continues and reduces maneuvering margins. Global sales of the arthritis treatment amounted to $993 million in the third quarter, significantly missing the forecasts of $1.15 billion and marking a symbolic milestone: for the first time since losing its exclusivity, Humira has established itself below one billion dollars in quarterly revenue. This transition forces AbbVie to accelerate its strategic transformation, with the group having already invested over $20 billion in acquisitions to fill this gap in its product portfolio.